Good morning, everyone, and nice to be back after an extended weekend break. Nonetheless, time flies, as they say, and once again, we are staring down a bulging to-do list. To cope, yes, we are brewing cups of stimulation — our choice today is cinnamon dolce — and we invite you to join us. The neurons could use a little help, you know? Meanwhile, here are a few items of interest to help you on your own journey. We hope today is productive and you conquer the world, such as it is. Stay in touch and stay safe. …

Former Vice President Joe Biden is winning the race for donations from drug makers, but experts and industry stakeholders doubt his plans will successfully lower drug prices or address underlying issues in the industry, Newsweek explains. The pharmaceuticals and health products industry has donated more than $5.9 million to Biden’s presidential campaign, while President Trump has garnered less than $1.5 million in donations from the industry, based on figures through Sept. 21.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy